These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 14565328)
1. In vitro study of resistance-associated genotypic mutations to nucleoside analogs. Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328 [TBL] [Abstract][Full Text] [Related]
2. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732 [TBL] [Abstract][Full Text] [Related]
4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Miller V; Larder BA Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471 [TBL] [Abstract][Full Text] [Related]
5. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734 [TBL] [Abstract][Full Text] [Related]
6. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476 [TBL] [Abstract][Full Text] [Related]
7. [In vitro selection and phenotyping of HIV-1 mutants resistant to azidothymidine and didanosine]. Kiseleva IaIu; Pliasunova OA; Pokrovskaia NV; Pokrovskiĭ AG Antibiot Khimioter; 2005; 50(5-6):11-6. PubMed ID: 16526603 [TBL] [Abstract][Full Text] [Related]
8. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197 [TBL] [Abstract][Full Text] [Related]
10. In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir. Park SS; Hong SK; Lee SG; Yoon JS; Yoo WC; Paik SY Nucleosides Nucleotides Nucleic Acids; 2007; 26(5):453-7. PubMed ID: 17578743 [TBL] [Abstract][Full Text] [Related]
11. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026 [TBL] [Abstract][Full Text] [Related]
12. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778 [TBL] [Abstract][Full Text] [Related]
13. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. Ross L; Johnson M; Graham N; Shaefer M; St Clair M J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735 [TBL] [Abstract][Full Text] [Related]
14. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877 [TBL] [Abstract][Full Text] [Related]
15. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Domaoal RA; Demeter LM Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341 [TBL] [Abstract][Full Text] [Related]
16. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792 [TBL] [Abstract][Full Text] [Related]
17. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543 [TBL] [Abstract][Full Text] [Related]
18. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771 [TBL] [Abstract][Full Text] [Related]
19. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731 [TBL] [Abstract][Full Text] [Related]